actualités
16/10 2023
The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities
23/08 2023
In countries like Niger, there is a painkiller shortage, not an addiction
19/01 2023
Research article on access to opioid analgesics for medical use in DRC
14/02 2022
PV du webinaire Qualité des produits de santé essentiels dans les pays de l'Afrique francophone
03/12 2021
DES PRODUITS POUR LE COVID-19 DE QUALITÉ INFÉRIEURE OU FALSIFIÉS : UN RAPPORT EN FRANCAIS Depuis le début de la pandémie, le Medicine Quality Research Group a identifié 845 articles pertinents sur les problèmes de qualité des produits médicaux pour la COVID-19.
01/06 2021
Fighting poor quality health products in times of COVID-19 and beyond: the need for a multi-stakeholder approach
18/01 2021
Towards a new structural approach to pharmaceutical innovation, intellectual property and public health: If not now, when?
12/10 2020
Open-access paper: QA systems pharmaceutical distributors LMICs Weaknesses Ways forward
25/09 2020
Short course in Pharmaceutical policies in health systems at ITM (June 2021)
06/12 2018
Seminar on Access to Quality-assured medicines The Be-cause health seminar on building universal access to quality-assured medicines gathered over 80 participants at the DGD headquarters in Brussels on November 20th, for looking at how national and international funding agencies, as well Belgian stakeholders, can contribute to this aim.
05/12 2018
Medicines and ethics Poor-quality medicines are especially prevalent in low- and middle-income countries. They represent a threat for individual and public health, by causing therapeutic failure or direct toxicity, by contributing to the emergence of resistance, and by eroding trust in health systems. Unfortunately, they often go undetected (due to the lack of efficient reporting systems), or they are only detected after treatment failure or toxicity become evident.
20/06 2018
A call for strengthening the regulatory capacities of pharmaceuticals in the South Poor-quality medicines are still a major and hidden threat to many individuals and health systems in low-income countries. The collaboration between ITM researchers, master’s students and QUAMED (Quality Medicines for All) on the quality systems of pharmaceutical distributors provides an opportunity to share the findings of operational actors with the public health community.
17/01 2018
Plenary talk of prof. Hogerzeil at ECTMIH on essential medicines The plenary talk of prof. Hogerzeil at ECTMIH on essential medicines is now available online.
26/10 2017
Ministre De Croo et les acteurs belges actifs dans la coopération internationale en santé signent un engagement sur les médicaments de qualité La Coopération au développement belge veillera davantage à la qualité des produits pharmaceutiques dans les pays en développement.
12/10 2017
Poor quality medicines on the programme at ECTMIH, Belgium Dr Raffaella Ravinetto, senior researcher at the ITM Public Health Department and chair of the Be-cause health Medicines Working Group, said: “Despite an increasing awareness of the problem of poor quality medicines, the divide in pharmaceutical quality between the North and the South remains insufficiently addressed.
10/08 2016
Publication par Jacques Pinel Publication par Jacques Pinel († 2015), un pionnier de la lutte pour l’accès universel à des médicaments de qualité, intitulée "Les médicaments de contrefaçons et sous-standards : un danger de mort. Exceptionnel dans les pays industrialisés, commun dans les pays en développement."